TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Provided By PR Newswire

Last update: May 15, 2025

Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda^® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA), in Q2 2025